Range of work
The Drug Development Office has a broad remit and our world-class portfolio covers a spectrum of cancer types and modes of anti-cancer therapy. Since 1980 we have advanced over 100 novel anti-cancer agents through various stages of pre-clinical and early phase clinical trials. Our challenge is to further increase our breadth and impact, and focus on areas of need, in line with Cancer Research UK’s research strategy.
Our portfolio has included:

- Vaccines
- Antibody
- Antisense oligonucleotide
- Cell therapy
- Co-agent combination
- Gene therapy
- Imaging agent
- Oncolytic virus
- Polymer therapeutic
- Small molecule







Read article